Akèy › Kansè Poumon ki pa ti selil › Pennsylvania › Philadelphia
Etid klinik pou Kansè Poumon ki pa ti selil nan Philadelphia, PA
51 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Philadelphia (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- Temple University Hospital, Philadelphia
- ak 5 plis
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #98, Philadelphia
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Ap rekriteFaz 3
- Perelman Center for Advanced Medicine ( Site 3205), Philadelphia
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- Lankenau Medical Center, Wynnewood · 7 mi lwen
- ak 2 plis
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Alliance Cancer Specialists, PC, Wynnewood · 7 mi lwen
- Consultants in Medical Oncology and Hematology, P.C., Broomall · 10 mi lwen
- Alliance Cancer Specialists, PC, Media · 12 mi lwen
- ak 1 plis
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Ap rekriteFaz 3
- Alliance Cancer Specialists - Media, Media · 12 mi lwen
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Philadelphia
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- University of Pennsylvania, Philadelphia
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Thomas Jefferson University Hospital, Philadelphia
- Jefferson Health Northeast, Philadelphia
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Ap rekriteFaz 1
- Research Site, Philadelphia
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- Lankenau Medical Center, Wynnewood · 7 mi lwen
- Riddle Memorial Hospital, Media · 12 mi lwen
- Paoli Memorial Hospital, Paoli · 18 mi lwen
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- Jefferson Hospital Northeast, Philadelphia
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- Local Institution - 0504, Philadelphia
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- Lankenau Medical Center, Paoli · 18 mi lwen
An External Control Arm Study in Non-Small Cell Lung Cancer
Ap rekriteEtid obsèvasyon
- Main Line Health, Wynnewood · 7 mi lwen
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- Hospital of the University of Pennsylvania, Philadelphia
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Site, Philadelphia
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Ap rekriteEtid obsèvasyon
- University of Pennsylvania, Philadelphia
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Thomas Jefferson University, Sidney Kimmel Cancer Center - Clinical Trials Office, Philadelphia
- USO - Alliance Cancer Specialists, PC, Horsham · 16 mi lwen
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Ap rekriteFaz 3
- Thomas Jefferson University - Clinical Research Institute ( Site 0147), Philadelphia
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
Ap rekriteFaz 1/2
- Thomas Jefferson University Research Facility, Philadelphia
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- Thomas Jefferson University, Philadelphia
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- Fox Chase Cancer Center, Philadelphia
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Ap rekriteEtid obsèvasyon
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Ap rekriteFaz 1/2
- Abramson Cancer Center of the University of Pennsylvania ( Site 0010), Philadelphia
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Ap rekriteFaz 1
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Ap rekriteFaz 2
- Abramson Cancer Center ( Site 0010), Philadelphia
TCR1188-ABC Cells in KRAS-mutated Cancers
Ap rekriteFaz 1
- University of Pennsylvania, Philadelphia
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Ap rekriteFaz 1/2
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Thomas Jefferson University, Philadelphia
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Ap rekriteFaz 1
- Jefferson University Hospitals, Philadelphia
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- Fox Chase Cancer Center, Philadelphia
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 3
- Thomas Jefferson University Hospital, Philadelphia
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Ap rekriteFaz 3
- Abramson Cancer Center, Philadelphia
MOv19-BBz CAR T Cells in FRa+ Cancers
Ap rekriteFaz 1
- University of Pennsylvania, Philadelphia
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
Ap rekriteFaz 2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- Perelman Center for Advanced Medicine /ID# 250188, Philadelphia
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · 8 mi lwen
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Ap rekriteFaz 2
- Fox Chase Cancer Center, Philadelphia
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Fox Chase Cancer Center, Philadelphia
- Temple University Hospital, Philadelphia
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · 8 mi lwen
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Ap rekriteFaz 2
- Fox Chase Cancer Center, Philadelphia
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Ap rekriteFaz 1/2
- Univ of Pennsylvania, Abramson Cancer Center, Philadelphia
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Ap rekriteFaz 2
- University of Pennsylvania, Philadelphia
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Fox Chase Cancer Center, Philadelphia
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Ap rekriteFaz 1/2
- University of Pennsylvania, Philadelphia
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of Pennsylvania, Philadelphia
The Impact of Surgical Technique on Circulating Tumor DNA in Stage I-III Non-Small Cell Lung Cancer
Ap rekrite
- Jefferson Health Northeast, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
- Abington Memorial Hospital, Abington · 12 mi lwen
- ak 1 plis
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Ap rekriteFaz 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Philadelphia
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Philadelphia
- Kansè (tout kalite)59 etid
- Kansè nan tete56 etid
- Kansè Metastatik46 etid
- Kansè pwostat44 etid
- Kansè kolorektal44 etid
- Kansè ovè44 etid
- Kansè poumon36 etid
- Leksemi mieloïd egi34 etid
- Ensifizyans kadyak31 etid
- Kansè Endomèt28 etid
- Depresyon26 etid
- Kansè pankreyas26 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.